World News: 12:31 GMT Friday 7th December 2018. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Dec. 07, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering. The apheresis market was valued at USD 1,788 million in 2017 and is expected to register a CAGR of about 10.89% during the forecast period 2018-2023.
Apheresis has recently witnessed a great demand due to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders. It is also found in patients with autoimmune diseases. Cancers, such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes (MDS) are the types of cancer that can affect the bone marrow, the blood cells, the lymph nodes, and other parts of the lymphatic system.
It has been observed that apheresis technology has been used in order to reduce the number of white cells until they can be controlled by other medications. According to the Leukemia & Lymphoma Society (LLS), approximately for every three minutes, one person in the United States is diagnosed with blood cancer. An estimated combined total of 174,250 people in the United States are expected to be diagnosed with leukaemia, lymphoma, or myeloma in 2018.
According to the Cancer Research UK, it is estimated that the incidence rates for leukaemia are projected to rise by about 5% in the United Kingdom between 2014 and 2035, to 19 cases per 100,000 people by 2035. Along with these main disease conditions, the technology has also been widely used for the treatment of conditions, such as myasthenia gravis, systemic lupus disease, severe rheumatoid arthritis, and in cases of selected organ transplantation with a high risk of antibody-mediated rejection of the transplant.
Use of apheresis in clinically ill patients is increasing day by day. It has been widely used as a primary therapy or as an adjunct to other therapies for various diseases, such as thrombotic thrombocytopenic purpura, haemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.
With the steady increase in the number of patients suffering from these diseases, ailments, and the technical ease of using these devices in the treatment of these diseases, requiring a minimal hospital stay, the global apheresis market is poised to grow during the forecast period.
The cost of providing the apheresis therapy is a matter of almost universal concern. Estimates of the costs of individual apheresis treatments are very much available but vary widely.
For instance, in the United States, the cost of an apheresis procedure is approximately USD 2500 per treatment, which is very high. An investment of USD 19,000 to USD 32,000 for a blood cell separator is the initial cost for setting up the machine and disposable sets produced by manufacturers will vary between USD 40 and USD 90 per treatment. Replacement fluids (at an average volume of 2.8 litres), such as albumin or fresh frozen plasma, make up the remainder of the costs, running USD 125 to USD 600 per treatment.
Also, apheresis was routinely reimbursed by some third parties when prescribed by a physician. However, concerned about costs and estimates of expansion of use over the next five years, third-party payers are now attempting to tailor their policies according to the principle of appropriate use i.e., to pay for apheresis where and when it is a proven and efficient therapeutic method.
Also, there are various studies on the cost of mobilization and apheresis of peripheral blood stem cell (PBSC) that demonstrate the process is costly and that the cost increases with the increase of the number of mobilization attempts.
In India, the apheresis machine costs Rs.17.5 lakh and there is an apheresis kit which is required for separating components costing INR 10,000, which is very costly for low-income individuals to afford. Thus, high capital investment and cost associated with this procedure is acting as a major restraint for the growth of the market.
North America is expected to have the largest market share owing to the highly sophisticated healthcare infrastructure and high healthcare expenditure. In addition, a high patient awareness, the demand for plasma-derived medicines, and the rise in the disposable income make this region dominant in the market.
Asia-Pacific is also expected to grow at a high rate during the forecast period due to a considerably well-established apheresis market in Japan, moreover, the emerging economies, such as India and China, have large patients pool, geriatric population, and rising healthcare expenditure.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Blood Banking
Globe Newswire: 12:31 GMT Friday 7th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.